Did management answer the analysts?
12 analyst questions audited, 5 evaded or deflected.
View Claim Ledger →Birlasoft reported a mixed Q4 FY26 with revenue of ₹1,348.6 crore (+0.1% QoQ, +2.4% YoY) but dollar revenue declined 2.7% QoQ to $145.3 million.
✓ Verified against BSE filing
Birlasoft reported a mixed Q4 FY26 with revenue of ₹1,348.6 crore (+0.1% QoQ, +2.4% YoY) but dollar revenue declined 2.7% QoQ to $145.3 million. EBITDA margin expanded 30bps QoQ to 18.5%, aided by one-offs and forex tailwinds. PAT surged 46.7% QoQ to ₹175.9 crore. Full-year revenue fell 1.2% in INR and 6% in USD, impacted by client-specific issues, productivity pass-throughs, and deliberate exit from low-margin business. Management highlighted a soft demand environment and delayed decision-making. They are investing heavily in sales (30-40% increase in headcount by mid-FY27) and new leadership to drive growth. However, they refrained from providing revenue guidance due to volatility. Key risk: sustained macro headwinds and competitive intensity from larger players could delay the expected turnaround.
12 analyst questions audited, 5 evaded or deflected.
View Claim Ledger →0 delivered, 0 close, 2 missed.
View Promises →Sustained macroeconomic headwinds and tariff uncertainty
View Risks →Full transcript text is available on this route.
Read Transcript →Second consecutive quarter above $200M; net new TCV was soft due to delayed decisions.
Targeted increase in sales team strength by mid-FY27 to boost pipeline.
Adjusted for spillover collections, DSO would have been 55 days.
Board proposed final dividend of ₹4 per share, total FY26 dividend ₹6.50.
Management plans to expand sales headcount significantly, with most additions in US and Europe, to drive pipeline and order booking.
CFO stated that elevated ETR due to US tax provisions was limited to FY26, and ETR should settle closer to historical levels starting FY27.
CFO reiterated that sustainable EBITDA margin is expected to be upward of 15%, with current elevated levels eroding due to investments and productivity pass-throughs.
Management expects total contract value in Q4 to be higher than the $202 million achieved in Q3.
A wage hike will be implemented between Q1 and Q2 of next financial year, with promotions already underway.
Management cited volatile demand due to trade tariffs and geopolitics, which could continue to delay client decisions and impact revenue.
Analyst raised that larger vendors are competing for smaller deals; management confirmed this trend, which could pressure win rates and pricing.
Management acknowledged that AI deals require upfront productivity benefits, leading to near-term revenue compression before potential recovery.
Multiple new leaders and a 30-40% sales expansion may take time to yield results; past restructuring cycles have not delivered growth.
Renewals are expected at lower margins due to pricing pressure, which could compress overall margins.
The one-off growth in manufacturing/ERP in Q3 will not repeat, and these segments are expected to remain soft in Q4.
Three fewer working days in Q4 could impact revenue, though partially mitigated by fixed-price contracts.
Pricing pressure in healthcare due to tariff uncertainties may persist into Q4 and Q1 FY27.
Mentioned in Q1 FY26, Q3 FY26
Steady-state EBITDA margin expected to be around 15% excluding one-off benefits and forex tailwinds, factoring in investments and pricing pressure.
Mentioned in Q1 FY26, Q3 FY26
Renewals are expected at lower margins due to pricing pressure, which could compress overall margins.
Management plans to expand sales headcount significantly, with most additions in US and Europe, to drive pipeline and order booking.
Management cited volatile demand due to trade tariffs and geopolitics, which could continue to delay client decisions and impact revenue.
View Risks →